📊 MIRA Key Takeaways
Is Mira Pharmaceuticals, Inc.. (MIRA) a Good Investment?
Mira is a pre-revenue stage pharmaceutical company with minimal commercial traction ($44.9K revenue, declining -40.3% YoY) and significant operating cash burn ($1.2M annually), resulting in a net margin of -2561%. While the strong balance sheet ($9.3M equity, zero debt) and improving loss trend (+67.4% YoY) provide financial runway, the absence of any meaningful business fundamentals or demonstrated commercialization capability makes the company unsuitable for fundamental-based investment at this stage.
MIRA Pharmaceuticals shows very weak operating fundamentals: revenue is minimal and declining, net losses remain extremely large relative to sales, and operating cash flow is deeply negative. The balance sheet is currently a mitigating factor, with strong cash, high liquidity, and essentially no debt, but the business still appears dependent on external funding unless it materially improves commercialization or clinical progress.
Why Buy Mira Pharmaceuticals, Inc.. Stock? MIRA Key Strengths
- Exceptionally strong liquidity position (82.16x current ratio) with minimal financial distress risk
- Zero long-term debt with $4.8M cash reserves representing 51% of total assets
- Improving loss trajectory with net income losses declining 67.4% year-over-year
- Strong liquidity position with $6.35M in cash and a 15.75x current ratio
- Very low leverage, with negligible debt and over $10M in equity
- Asset base is largely funded by equity rather than liabilities, reducing near-term balance sheet stress
MIRA Stock Risks: Mira Pharmaceuticals, Inc.. Investment Risks
- Virtually non-existent revenue base ($44.9K) with accelerating -40.3% YoY revenue decline
- Substantial ongoing operating cash burn ($1.2M annually) against minimal revenue generation
- Typical biotech execution risk with unproven pipeline and unclear path to commercialization; cash runway approximately 4 years at current burn rate
- Revenue is tiny and fell 40.3% year over year, indicating weak commercial traction
- Net margin of -10557.5% and negative operating cash flow of $4.66M point to an unsustainable earnings profile
- Likely need for future capital raises if cash burn continues without meaningful revenue growth
Key Metrics to Watch
- Revenue growth rate reversal from -40.3% decline
- Operating cash burn trajectory and monthly burn rate
- Clinical pipeline development milestones and regulatory progress
- Quarterly operating cash burn relative to cash balance
- Revenue growth and any improvement in net loss margin
Mira Pharmaceuticals, Inc.. (MIRA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 82.16x current ratio provides a solid financial cushion.
MIRA Profit Margin, ROE & Profitability Analysis
MIRA vs Healthcare Sector: How Mira Pharmaceuticals, Inc.. Compares
How Mira Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Mira Pharmaceuticals, Inc.. Stock Overvalued? MIRA Valuation Analysis 2026
Based on fundamental analysis, Mira Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Mira Pharmaceuticals, Inc.. Balance Sheet: MIRA Debt, Cash & Liquidity
MIRA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Mira Pharmaceuticals, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
MIRA Revenue Growth, EPS Growth & YoY Performance
Mira Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
MIRA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Mira Pharmaceuticals, Inc.. (CIK: 0001904286)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MIRA
What is the AI rating for MIRA?
Mira Pharmaceuticals, Inc.. (MIRA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MIRA's key strengths?
Claude: Exceptionally strong liquidity position (82.16x current ratio) with minimal financial distress risk. Zero long-term debt with $4.8M cash reserves representing 51% of total assets. ChatGPT: Strong liquidity position with $6.35M in cash and a 15.75x current ratio. Very low leverage, with negligible debt and over $10M in equity.
What are the risks of investing in MIRA?
Claude: Virtually non-existent revenue base ($44.9K) with accelerating -40.3% YoY revenue decline. Substantial ongoing operating cash burn ($1.2M annually) against minimal revenue generation. ChatGPT: Revenue is tiny and fell 40.3% year over year, indicating weak commercial traction. Net margin of -10557.5% and negative operating cash flow of $4.66M point to an unsustainable earnings profile.
What is MIRA's revenue and growth?
Mira Pharmaceuticals, Inc.. reported revenue of $44.9K.
Does MIRA pay dividends?
Mira Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find MIRA SEC filings?
Official SEC filings for Mira Pharmaceuticals, Inc.. (CIK: 0001904286) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MIRA's EPS?
Mira Pharmaceuticals, Inc.. has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MIRA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Mira Pharmaceuticals, Inc.. has a SELL rating with 66% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MIRA stock overvalued or undervalued?
Valuation metrics for MIRA: ROE of -12.3% (sector avg: 15%), net margin of -2,561.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MIRA stock in 2026?
Our dual AI analysis gives Mira Pharmaceuticals, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MIRA's free cash flow?
Mira Pharmaceuticals, Inc..'s operating cash flow is $-1.2M, with capital expenditures of N/A. FCF margin is -2,674.9%.
How does MIRA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,561.1% (avg: 12%), ROE -12.3% (avg: 15%), current ratio 82.16 (avg: 2).